SLC5A2 and chronic kidney disease: The available data to date from secondary or subanalyses of trials, simulation type analyses from recent studies, and real world data suggest potential complementary and additive effects; and in our opinion, combination treatment of GLP-1 RA and SGLT-2 inhibitors should be considered early in the management of CKD in people with diabetes.49